tradingkey.logo

Eton Pharmaceuticals Inc

ETON
View Detailed Chart

18.460USD

+0.780+4.41%
Close 09/18, 16:00ETQuotes delayed by 15 min
495.05MMarket Cap
LossP/E TTM

Eton Pharmaceuticals Inc

18.460

+0.780+4.41%
Intraday
1m
30m
1h
D
W
M
D

Today

+4.41%

5 Days

+5.07%

1 Month

+12.77%

6 Months

+25.75%

Year to Date

+38.59%

1 Year

+212.35%

View Detailed Chart

TradingKey Stock Score

Currency: USD Updated: 2025-09-18

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking
54 / 175
Overall Ranking
156 / 4721
Industry
Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 3 analysts
Buy
Current Rating
30.000
Target Price
+69.68%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks
Eton Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company has six commercial rare disease products: INCRELEX, ALKINDI SPRINKLE, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone. INCRELEX is a biologic product used to treat pediatric patients 2 years of age and older who suffer from severe primary insulin-like growth factor 1 deficiency (SPIGFD). ALKINDI SPRINKLE is for the treatment of pediatric adrenocortical insufficiency. Carglumic Acid is for the treatment of hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency. Betaine Anhydrous is for the treatment of homocystinuria. Nitisinone is for the treatment of hereditary tyrosinemia type 1 (HT-1). PKU GOLIKE is a medical formula for patients with phenylketonuria (PKU). Galzin, its product, is FDA-approved for the treatment of the ultra-rare metabolic condition of Wilson Disease.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 83.57% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 39.01M.
Undervalued
The company’s latest PE is -120.84, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 16.03M shares, decreasing 8.37% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 1.31M shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of 0.64.

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Eton Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company has six commercial rare disease products: INCRELEX, ALKINDI SPRINKLE, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone. INCRELEX is a biologic product used to treat pediatric patients 2 years of age and older who suffer from severe primary insulin-like growth factor 1 deficiency (SPIGFD). ALKINDI SPRINKLE is for the treatment of pediatric adrenocortical insufficiency. Carglumic Acid is for the treatment of hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency. Betaine Anhydrous is for the treatment of homocystinuria. Nitisinone is for the treatment of hereditary tyrosinemia type 1 (HT-1). PKU GOLIKE is a medical formula for patients with phenylketonuria (PKU). Galzin, its product, is FDA-approved for the treatment of the ultra-rare metabolic condition of Wilson Disease.
Ticker SymbolETON
CompanyEton Pharmaceuticals Inc
CEOMr. Sean E. Brynjelsen
Websitehttps://etonpharma.com/
KeyAI